One-Time Gene Edits for Heart Disease
Picture a side effect that hits one patient in 100,000. A trial of a few hundred people would probably never see it. Give the same one-time treatment to 10 million people, and about 100 could be harmed, with no pill to stop taking. Two University of Michigan cardiologists put that problem at the center of a new framework for permanent genetic treatments, arguing that a single gene edit could protect against high cholesterol and heart disease for decades, but only if it clears five tests.
Key Takeaways
- University of Michigan cardiologists propose five criteria for deciding when a one-time gene edit or gene therapy should be used for a common disease.
- Targets such as PCSK9, ANGPTL3 and TTR could allow single treatments for high cholesterol, atherosclerosis and amyloidosis instead of lifelong medication.
- Permanent changes cannot be stopped like a drug, rare side effects could affect many people at scale, and some gene therapies already cost more than $1 million.
From Rare Diseases to Everyday Ones
Gene therapies have already changed care for spinal muscular atrophy and sickle cell disease. Those are rare conditions with few alternatives. More than 6,000 rare disorders have been identified, but only a small share have targets that can be treated today.
The next wave aims much wider. The authors, Eric D. Smith and Venkatesh L. Murthy of the University of Michigan Health Frankel Cardiovascular Center, write that “Genomic therapy has moved from futurism to clinical reality.”
Candidates include silencing or editing genes such as PCSK9, ANGPTL3 and TTR to treat atherosclerosis, abnormal blood fats and amyloidosis. Gene replacement could address inherited cardiomyopathies. Early studies already test whether one treatment can lower LDL, or “bad,” cholesterol for years.
A one-time fix has obvious appeal. Many patients struggle to take daily pills or regular injections as prescribed. Long-acting drugs are moving in the same direction, such as an experimental Lilly drug that cut a genetic heart risk factor by nearly 94%.
The Five Tests
The first test is severity: how serious is the disease, and how much could patients gain? The second asks whether effective treatments already exist that doctors can adjust or stop. For high cholesterol, heart disease, obesity and diabetes, they usually do.
The third test looks at durability, meaning whether the target tissue suits a treatment meant to last after one dose. The fourth weighs the risks of delivering the therapy against the severity of the disease. The fifth asks whether researchers can track safety and results for years, and at large scale.
Why Permanence Cuts Both Ways
Therapies can add working copies of a gene, silence harmful gene activity or rewrite DNA directly. Many rely on modified viruses to carry the instructions into cells. Researchers are also developing non-viral routes, such as nanoparticle-based gene editing for cystic fibrosis.
The immune system can learn to recognize viral carriers. That can make a second dose difficult or impossible, even if the benefit fades over time.
A drug can be stopped. A permanent edit generally cannot. Scientists may one day build in “off-switches” or other ways to reverse a treatment, but none has yet proven reliable.
Clinical trials tend to be small and short, so they can miss rare or delayed problems. Patient registries have shown the value of long follow-up. Widely used therapies, the authors argue, would need independent, standardized monitoring at far larger scale.
These treatments target somatic cells, the non-reproductive cells of the body. They are not meant to create changes that children inherit, unlike germline editing.
Price is another hurdle. Some gene therapies already carry list prices above $1 million per patient, and several cost substantially more.
Cardiology Is Already Testing the Idea
The question is no longer theoretical. In November 2025, researchers reported that a single CRISPR infusion roughly halved LDL cholesterol and triglycerides in an early trial targeting ANGPTL3. Drugmakers have taken notice too, with Eli Lilly buying base-editing company Verve Therapeutics in 2025.
Medical societies are drawing their own lines. In March, the American College of Cardiology issued a scientific statement on gene editing in cardiovascular care. It called lipid nanoparticles a promising delivery route for liver targets, but warned about long safety follow-up, unclear comparisons with existing drugs and the economics of costly one-time cures. The Michigan framework turns those concerns into a checklist doctors and regulators can apply when deciding which patients should go first.
Written by Alius Noreika